Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441694 · ClinicalTrials.gov registry record · Phase 1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT07441694 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 218 participants, above the 124-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT07441694, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Conditions Studied
Interventions
- DRUG INCA036978
- DRUG Standard disease-directed therapy
Study Locations (20)
California
- City of Hope-Lennar Foundation Cancer Center - Irvine
- Usc Norris Comprehensive Cancer Center - Los Angeles
- UCLA Medical Hematology & Oncology - Los Angeles
North Carolina
- University of North Carolina At Chapel Hill - Chapel Hill
- Levine Cancer Institute - Charlotte
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy - Durham
Florida
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
New York
- Mount Sinai School of Medicine - New York
- Weill Cornell Medicine - New York
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Alabama
- University of Alabama At Birmingham - Birmingham
Connecticut
- Yale Cancer Center - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2026-03-29 |
| Est. Completion | 2030-05-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441694
The ClinicalTrials.gov registry entry for NCT07441694 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (76% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which INCA036978 is the first listed.
NCT07441694 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT07441694 about?
NCT07441694 is a clinical study titled "Study of INCA036978 in Participants With Myeloproliferative Neoplasms". This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
What is the current status of trial NCT07441694?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 218 participants. The study started on 2026-03-29. Estimated completion is 2030-05-24.
What conditions does trial NCT07441694 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT07441694?
The interventions under investigation include: INCA036978 (DRUG), Standard disease-directed therapy (DRUG).
Who is sponsoring clinical trial NCT07441694?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07441694 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
ACTIVE NOT RECRUITING · Phase 1
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.